As pharma DTC platforms continue to expand, regulators will keep an eye on how discounted drugs are sold — and even advertised — in ways that don’t violate anti-kickback laws.
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. One area that continues to raise red flags across the ...
In the spring of 2025, two federal courts issued decisions interpreting the federal Anti-Kickback Statute, with one court narrowing the conduct that is prohibited while the other court refused to do ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results